The effect of Pyridostigmine on patients with CRPS-1.

Pyridostigmine: using a cholinesterase inhibitor to activate the cholinergic anti-inflammatory pathway in patients with CRPS-1.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON20521

Enrollment

Registered

2009-02-09

Start date

2009-04-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

complex regional pain syndrome, neuropathic pain, neurogenic inflammation,

Interventions

Pyridostigmine in an individual dosage.

Eligibility

Inclusion criteria

Inclusion criteria: Patients with CRPS-1 according to Veldman criteria, autonomic alterations like hypo/hyper hydrosis, altered hair/nail growth, unsatisfactory results of standard treatment, ability to give informed consent, age >18.

Exclusion criteria

Exclusion criteria: CRPS-1 or other condition on contralateral extremity, asthma, cardiac problems, hyperthyroidism, epilepsy, parkinson, kydney dysfunction, severe psychiatric dysfunction, history of digestive tract operation or ulcers, active malignant disease, other chronic pain syndrome, use of anti-cholinergic medication.

Design outcomes

Primary

Measure	Time frame
1. Pain (VAS score); 2. Motor funcion (AROM); 3. Swelling; 4. Temperature.	—

Secondary

Measure	Time frame
1. Autonomic functioning; 2. Blood analysis on oxidative stress; 3. Acetylcholine status.	—

Contacts

Public ContactS.G.L. Fischer

VUmc, afdeling 6F kamer 002, anesthesiologie Postbus 7057

s.fischer@vumc.nl+31 (0)20-4440293

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)